Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Durable Response to PD1 Inhibitor Pembrolizumab in a Metastatic, Metaplastic Breast Cancer ; volume:14 ; number:2 ; year:2021 ; pages:931-937 ; extent:7
Case reports in oncology ; 14, Heft 2 (2021), 931-937 (gesamt 7)
- Creator
-
Gorshein, Elan
Matsuda, Kant
Riedlinger, Gregory
Sokol, Levi
Rodriguez-Rodriguez, Lorna
Eladoumikdachi, Firas
Grandhi, Miral
Ganesan, Shridar
Toppmeyer, Deborah L.
Potdevin, Lindsay
Toomey, Kathleen
Hirshfield, Kim M.
Chan, Nancy
- DOI
-
10.1159/000515510
- URN
-
urn:nbn:de:101:1-2021090900440203354791
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gorshein, Elan
- Matsuda, Kant
- Riedlinger, Gregory
- Sokol, Levi
- Rodriguez-Rodriguez, Lorna
- Eladoumikdachi, Firas
- Grandhi, Miral
- Ganesan, Shridar
- Toppmeyer, Deborah L.
- Potdevin, Lindsay
- Toomey, Kathleen
- Hirshfield, Kim M.
- Chan, Nancy
Other Objects (12)
Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pembrolizumab
Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma
Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pembrolizumab
Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors
Durable Response to Pazopanib in Recurrent Metastatic Carotid Body Paraganglioma
Durable Response with Single-Agent Pembrolizumab in a Patient with Metastatic Melanoma
Metastatic SMARCB1-Deficient Renal Medullary Carcinoma without Hemoglobinopathy with Durable and Dramatic Response to Pembrolizumab plus Lenvatinib: Case Report
Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
Pembrolizumab as first-line treatment for metastatic uveal melanoma
Proton pump inhibitors and potassium competitive acid blockers decrease pembrolizumab efficacy in patients with metastatic urothelial carcinoma
Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma
KRAS4A and KRAS4B in liquid biopsy of metastatic lung adenocarcinoma patients treated with Pembrolizumab or chemotherapy plus Pembrolizumab
Pembrolizumab
Major Durable Response of Pembrolizumab in Chemotherapy Refractory Small Cell Bladder Cancer: A Case Report
Near complete response to Pembrolizumab in microsatellite-stable metastatic sebaceous carcinoma
A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors